Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel
NASDAQ:IMNM

Immunome Q3 2025 Earnings Report

Immunome logo
$18.38 +0.02 (+0.11%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$18.38 0.00 (0.00%)
As of 06/12/2026 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immunome EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.57
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q3 2025
Date
11/6/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Immunome's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunome's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Immunome's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Immunome Earnings Headlines

Immunome's (IMNM) Outperform Rating Reaffirmed at Wedbush
June 13 at 3:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30836401
Immunome shareholders reaffirm board, auditor and pay policies
June 12 at 5:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immunome-shareholders-reaffirm-board-auditor-and-pay-policies?utm_source=marketbeat.com&utm_medium=referral
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.tc pixel
 |  InvestPub (Ad)
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
June 11 at 7:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260611016477/en/immunome-announces-first-patient-dosed-in-phase-1-trial-evaluating-im-1617-a-potential-first-in-class-adc-in-patients-with-advanced-solid-tumors/
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
June 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913364-immunome-inc-imnm-presents-at-goldman-sachs-47th-annual-global-healthcare-conference-2026
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
June 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913158-immunome-stock-varegacestat-is-the-beachhead-but-the-adc-engine-is-the-thesis
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use.

Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.

View Immunome Profile
Earnings Tools